Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

PayPal has reported for 6 months of 2023

8/3/23 PYPL

Gas production at Yamal LNG slipped by a third

8/3/23 NVTK

Qualcomm reported for 9 months of fiscal 2023

8/3/23 QCOM

Rostelecom buys 35% of Megacampus educational platform

8/3/23 RTKM

Genetico reported for 6 months of 2023 by RAS

8/2/23 GECO

Moscow Exchange summarized results of trading in July

8/2/23 MOEX

Norinickel reported for 6 months of 2023 by IFRS

8/2/23 GMKN

Belon reported for 6 months of 2023 by RAS

8/2/23 BLNG

Tatneft reported for 6 months of 2023 by RAS

8/2/23 TATN

The Kraft Heinz announced a quarterly dividend

8/2/23 KHC